Amarin (AMRN) Stocks Continue To Decline Following A Strong End Last Week
Last week, Amarin (AMRN) stocks nudged up incredibly fast as a top analyst upgraded the stock from a “Neutral” to a “Buy” rating; moving the target price to 10% and insinuating strong upward growth. However, it seems as though the excitement about the upgrade died over the weekend because the stock is down so far this week. Currently (12:10), the stock is trading at $2.48 per share, down 12.98% so far today.
Outlook – When the upgrade happened, there wasn’t much surprise. Remember, Amarin (AMRN) stocks just had another big kick in February when analysts at SunTrust bank upgraded the stock. With that being said, I think the downtrends we’re seeing are a classic case of too much too fast. Investors got excited and let their emotions send the stock climbing further than it should have Thursday and Friday. As a result, we’re seeing a bit of a correction this week. Nonetheless, the stock is still a great long term investment option!
Cytori (CYTX) Stocks Are Down After An Impressive Run
Following the Cytori (CYTX) earning report, we started to see a rally in the stock. While the report showed that there were losses in the fourth quarter and in the entire year of 2014, for some reason, investors were still excited. Nonetheless, the stock is trading in the red so far today.
Outlook – As I’ve mentioned in the past, when I invest, I’m in it for the long run. With that said, I tend to invest in companies that are already generating profits and have a proven track record of doing so quarter after quarter. Unfortunately, Cytori (CYTX) is a company that’s currently operating as a loss; which is a major red flag for me. While I’d love to see growth long term, I wouldn’t be confident enough in their ability to profit until they’ve proven that they can do so.
Inovio Pharmaceuticals (INO) Stocks Look To Be Continuing The Uptrend
Yesterday, we saw a great jump in the value of Inovio Pharmaceuticals (INO) stocks following the release of the company’s earnings report. While the company did generate a loss throughout the year, the company was able to show promise in growth. This morning, the momentum seemed to turn the other way in morning trading. However, after falling to the day’s low of $7.88 per share at 9:50, we started to see an incredible recovery. Currently (11:25), Inovio Pharmaceuticals (INO) stock is trading at $8.30 per share for a loss of 0.12% so far today. The stock is on a strong uptrend at the moment; so, it could end the day in the green.
Outlook – As mentioned above, I’m not an investor that likes to funnel money into companies that have not proven that they are capable of generating profits consistently. Unfortunately, Inovio Pharmaceuticals (INO) falls into that category. However, depending on your unique investment goals, it may be an option for you.
Gilead Sciences (GILD) Stocks Fall Even After An Analyst Upgrade From S&P 500
Big news came in today as the S&P 500 announced that Gilead Sciences (GILD) would be moving up from position #92 to position #90. Unfortunately, investors don’t seem to be paying attention to the positive as news of a policy shift threatens dollars has started to break. As a result, Gilead Sciences (GILD) stocks are down today; falling 1.20% so far (12:32) to $100.08 per share.
Outlook – While policy changes surrounding the BioTech space may be a bit of a concern to me, I’m pretty impressed with what Gilead Sciences (GILD) has accomplished. They’ve made waves in advancements of treatments of Hepatitis C and several other ailments; and will continue to do so. With that said, I see this one in the green for the long run.
Amgen (AMGN) Stocks Are Down Today Following Major Growth Yesterday
Yesterday, investors were all over Amgen (AMGN) stocks as the company announced data gathered from Repatha phases 2 and 3. The data was overwhelmingly positive news, showing that the company is reaching goals with advancements in the cardiovascular treatment. However, the movement in the company’s stock value today isn’t so positive. So far today (12:39), the stock has lost 0.49% and is currently trading at $162.23 per share.
Outlook – While Amgen (AMGN) stocks may be on the decline today, when it comes to earnings, this company is known for producing profits. With that said, I see great things in the future of Amgen (AMGN) stocks!
What Do You Think?
Do you have an opinion on any of the stocks mentioned here? We’d love to see it in the comments below!